Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL

NCT05334823 is registered in ClinicalTrials.gov with Chongqing Precision Biotech Co., Ltd as lead sponsor.

NCT NCT05334823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05334823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Lead sponsor
Chongqing Precision Biotech Co., Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
January 26, 2022
Completion date
July 1, 2029
Enrollment
100 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, refractory acute lymphoblastic leukemia, relapsed pediatric all